Cannabis Science Invests In The Research And Development Of Cannabinoid Based Medications To Treat COPD And Asthma

IRVINE, CA–(Marketwired – June 23, 2017) – Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, is pleased to announce that it has invested in the research and development of new cannabinoid-based medications to treat Chronic Obstructive Pulmonary Disease (COPD) and Asthma. According to the Centers for Disease Control and Prevention, in the U.S. alone over 15 million people have been diagnosed with COPD, and over 25 million with Asthma.

Source: Cannabis Science Invests In The Research And Development Of Cannabinoid Based Medications To Treat COPD And Asthma

This site uses Akismet to reduce spam. Learn how your comment data is processed.